Boehringer Ingelheim and Sanofi have entered an alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies. Boehringer’s cell culture operations will provide contract manufacturing capacities to support the production of Sanofi’s biologics pipeline. Under the agreement, Sanofi will have access to Boehringer’s capabilities to transfer and manufacture therapeutic monoclonal antibodies for global market supply. Initial product transfers will begin in early 201...